{
  "ptid_time": "023_S_0217_2007-03-02",
  "img_path": "/data/qiuhui/data/adni/images/023_S_0217/2007-03-02/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 30,645 mm³, 17.1% below the reference mean. With a Z-score of -0.46 (32.2th percentile), this represents normal volume ; hippocampal volume measures 4,740 mm³, 27.0% below the reference mean. With a Z-score of -2.17 (1.5th percentile), this represents significant atrophy; whole brain volume measures 903,948 mm³, 2.6% below the reference mean. With a Z-score of -0.31 (37.7th percentile), this represents normal volume ; entorhinal cortex volume measures 2,510 mm³, 27.5% below the reference mean. With a Z-score of -1.49 (6.9th percentile), this represents mild atrophy; fusiform gyrus volume measures 13,863 mm³, 13.9% below the reference mean. With a Z-score of -1.05 (14.7th percentile), this represents mild atrophy; middle temporal gyrus volume measures 14,624 mm³, 18.9% below the reference mean. With a Z-score of -1.68 (4.6th percentile), this represents moderate atrophy. ",
  "text_data": "Age is 84.6 years. Gender is Female. Education: 18 years. MMSE: 27.0. Logical Memory: 0.0. APOEε4 alleles: 0.0. ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The patient shows significant hippocampal atrophy (Z-score -2.17, 1.5th percentile) and moderate atrophy in the middle temporal gyrus (Z-score -1.68, 4.6th percentile), which are key regions affected in Alzheimer's disease. Despite a normal MMSE score (27/30), the structural changes suggest neurodegeneration, likely in the early stages given the preserved global cognition.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely due to Alzheimer's pathology given the hippocampal and temporal lobe atrophy).  \n\n**Confidence:** **Medium** (high confidence in neurodegeneration, but MCI diagnosis is provisional due to the lack of detailed cognitive testing beyond MMSE).  \n\n*Note: A follow-up with comprehensive neuropsychological testing (e.g., episodic memory assessment) and CSF/fMRI biomarkers (e.g., amyloid/tau) would strengthen the diagnosis.*",
  "timestamp": "2025-07-26T02:38:53.387892"
}